oasis-1 oral semaglutide 50 mg obesity nejm 2023 In the OASIS 4 phase 3 trial, once-daily at a dose of 25 resulted in a greater mean reduction in body weight than placebo in participants with overweight or Oral Semaglutide 25 mg and

Bakery style, soft texture, USA-made

Semaglutide the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy

Citric acid helps GLP-1 Support dissolve more easily in water, preventing clumping and ensuring a smooth drinking experience

In a crossover trial evaluating semaglutide versus placebo as an add-on to automated insulin delivery therapy in adults with type 1 diabetes, the use of semaglutide was associated with an increased percentage of time spent within the target glucose range, along with reduced insulin requirements.

While the effects of GLP-1RAs have been extensively studied in the context of diet-induced obesity, their impact on physiology in other nutritional contexts have been less explored

- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake